Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data

Bohlius, Julia; Schmidlin, Kurt; Brillant, Corinne; Schwarzer, Guido; Trelle, Sven; Seidenfeld, Jerome; Zwahlen, Marcel; Clarke, Mike J; Weingart, Olaf; Kluge, Sabine; Piper, Margaret; Napoli, Maryann; Rades, Dirk; Steensma, David; Djulbegovic, Benjamin; Fey, Martin F; Ray-Coquard, Isabelle; Moebus, Volker; Thomas, Gillian; Untch, Michael; ... (2009). Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. Cochrane database of systematic reviews(3), CD007303. Chichester: WileyInterscience 10.1002/14651858.CD007303.pub2

[img]
Preview
Text
Bohlius CochraneDatabaseSystRev 2009.pdf - Published Version
Available under License Publisher holds Copyright.

Download (4MB) | Preview

BACKGROUND: Erythropoiesis-stimulating agents (ESAs) reduce anemia in cancer patients and may improve quality of life, but there are concerns that ESAs might increase mortality. OBJECTIVES: Our objectives were to examine the effect of ESAs and identify factors that modify the effects of ESAs on overall survival, progression free survival, thromboembolic and cardiovascular events as well as need for transfusions and other important safety and efficacy outcomes in cancer patients. SEARCH STRATEGY: We searched the Cochrane Library, Medline, Embase and conference proceedings for eligible trials. Manufacturers of ESAs were contacted to identify additional trials. SELECTION CRITERIA: We included randomized controlled trials comparing epoetin or darbepoetin plus red blood cell transfusions (as necessary) versus red blood cell transfusions (as necessary) alone, to prevent or treat anemia in adult or pediatric cancer patients with or without concurrent antineoplastic therapy. DATA COLLECTION AND ANALYSIS: We performed a meta-analysis of randomized controlled trials comparing epoetin alpha, epoetin beta or darbepoetin alpha plus red blood cell transfusions versus transfusion alone, for prophylaxis or therapy of anemia while or after receiving anti-cancer treatment. Patient-level data were obtained and analyzed by independent statisticians at two academic departments, using fixed-effects and random-effects meta-analysis. Analyses were according to the intention-to-treat principle. Primary endpoints were on study mortality and overall survival during the longest available follow-up, regardless of anticancer treatment, and in patients receiving chemotherapy. Tests for interactions were used to identify differences in effects of ESAs on mortality across pre-specified subgroups. The present review reports only the results for the primary endpoint. MAIN RESULTS: A total of 13933 cancer patients from 53 trials were analyzed, 1530 patients died on-study and 4993 overall. ESAs increased on study mortality (combined hazard ratio [cHR] 1.17; 95% CI 1.06-1.30) and worsened overall survival (cHR 1.06; 95% CI 1.00-1.12), with little heterogeneity between trials (I(2) 0%, p=0.87 and I(2) 7.1%, p=0.33, respectively). Thirty-eight trials enrolled 10441 patients receiving chemotherapy. The cHR for on study mortality was 1.10 (95% CI 0.98-1.24) and 1.04; 95% CI 0.97-1.11) for overall survival. There was little evidence for a difference between trials of patients receiving different cancer treatments (P for interaction=0.42). AUTHORS' CONCLUSIONS: ESA treatment in cancer patients increased on study mortality and worsened overall survival. For patients undergoing chemotherapy the increase was less pronounced, but an adverse effect could not be excluded.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Bohlius, Julia; Schmidlin, Kurt; Trelle, Sven; Zwahlen, Marcel; Fey, Martin and Egger, Matthias

ISSN:

1469-493X

ISBN:

19588423

Publisher:

WileyInterscience

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:09

Last Modified:

23 Jun 2015 14:34

Publisher DOI:

10.1002/14651858.CD007303.pub2

PubMed ID:

19588423

Web of Science ID:

000268037500030

BORIS DOI:

10.7892/boris.30199

URI:

https://boris.unibe.ch/id/eprint/30199 (FactScience: 191369)

Actions (login required)

Edit item Edit item
Provide Feedback